2 weeks Ago By ABMN Staff
Rhumbline Advisers bought a new position in Renovaro Inc. ( NASDAQ:RENB – Free Report ) during the 2nd quarter, Holdings Channel reports. The fund bought 45,197 shares of the company’s stock, valued at approximately $79,000.
Several other institutional investors have also bought and sold shares of RENB. Vanguard Group Inc. increased its position in Renovaro by 904.
0% during the first quarter. Vanguard Group Inc. now owns 3,916,672 shares of the company’s stock valued at $10,379,000 after acquiring an additional 3,526,565 shares during the last quarter.
Bank of New York Mellon Corp bought a new position in Renovaro during the 2nd quarter valued at about $220,000. Tidal Investments LLC purchased a new position in Renovaro during the 1st quarter valued at $98,000. Finally, SG Americas Securities LLC purchased a new position in Renovaro in the 1st quarter worth about $46,000.
Institutional investors own 71.41% of the company’s stock. Renovaro Stock Down 2.
0 % Shares of NASDAQ:RENB opened at $0.48 on Tuesday. The business’s 50 day moving average is $0.
68 and its 200 day moving average is $1.41. The stock has a market cap of $71.
29 million, a P/E ratio of -0.62 and a beta of 0.58.
Renovaro Inc. has a 52-week low of $0.42 and a 52-week high of $5.
25. Insider Buying and Selling at Renovaro Renovaro Profile ( Free Report ) Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.
Featured Articles Want to see what other hedge funds are holding RENB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Renovaro Inc. ( NASDAQ:RENB – Free Report ).
Receive News & Ratings for Renovaro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renovaro and related companies with MarketBeat.com's FREE daily email newsletter ..
